← Back to Search

ReActiv8 Neurostimulation for Chronic Lower Back Pain (ReActiv8-B Trial)

N/A
Waitlist Available
Research Sponsored by Mainstay Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥22 years, ≤75 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

ReActiv8-B Trial Summary

This trial is to see if ReActiv8 is a safe and effective treatment for adults with chronic low back pain when used with medical management.

Who is the study for?
This trial is for adults aged 22 to 75 with chronic low back pain lasting over 90 days despite medical treatment. Participants must have a qualifying pain score, evidence of lumbar muscle dysfunction, and be able to give informed consent and follow the study plan. Exclusions include drug use, certain surgical histories, worse leg than back pain, planned surgeries, BMI over 35, spinal conditions like stenosis or neurological deficits.Check my eligibility
What is being tested?
The ReActiv8 Implantable Neurostimulation System is being tested in this trial. It involves two levels of stimulation: low and patient-appropriate. The goal is to assess how safe and effective ReActiv8 is alongside usual medical care for treating chronic lower back pain.See study design
What are the potential side effects?
Potential side effects may include discomfort at the implant site, possible nerve or tissue damage from the implant procedure itself, infection risks associated with surgery or implants, changes in back pain sensation due to stimulation adjustments.

ReActiv8-B Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 22 and 75 years old.

ReActiv8-B Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cumulative Proportion of Responders Analysis (CPRA) for the Primary Endpoint to Compare Participants Responses Over a Full Range of Response Levels
Mean Change in Low Back Pain VAS
Responder Rate of Low Back Pain With No Increase in Pain Medications
+1 more
Secondary outcome measures
Change in European Quality of Life Score on Five Dimensions (EQ-5D)
Change in European Quality of Life Score on Five Dimensions (EQ-5D) at One Year
Change in Oswestry Disability Index (ODI)
+9 more
Other outcome measures
Change in Opioid Use for Treatment of Low Back Pain at One-Year
Clinical Global Impression of Change
Clinical Global Impression of Change at One Year
+3 more

ReActiv8-B Trial Design

2Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Group II: ControlExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Mainstay MedicalLead Sponsor
4 Previous Clinical Trials
394 Total Patients Enrolled
Chris Gilligan, MD, MBAStudy ChairBrigham and Women's Hospital

Media Library

ReActiv8 Implantable Stimulation System (Low Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT02577354 — N/A
Chronic Lower Back Pain Research Study Groups: Treatment, Control
Chronic Lower Back Pain Clinical Trial 2023: ReActiv8 Implantable Stimulation System (Low Stimulation) Highlights & Side Effects. Trial Name: NCT02577354 — N/A
ReActiv8 Implantable Stimulation System (Low Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02577354 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the geographical scope of this clinical research?

"Upstate Clinical Trials in Spartanburg, South carolina, Duke University Medical Center in Durham, North carolina and the University of California San Diego in La Jolla are amongst 17 sites that are accepting patients for this clinical trial."

Answered by AI

What criteria must be met to qualify for participation in this experiment?

"Prospective participants in this clinical trial must have low back pain and be aged between 22-75. A total of 204 patients are being enrolled for the study."

Answered by AI

What are the expected results of this experiment?

"The goal of this clinical trial, assessed over 120 days, is to analyse the cumulative proportion of responders for its primary endpoint. Secondary outcomes include a comparison on the European Quality Of Life Score On Five Dimensions (EQ-5D) and Subject Global Impression Of Change (SGIC), both at one year post-treatment. Additionally, Mean Change In Low Back pain Visual Analog Scale (VAS) will be measured after 12 months as well. After day 120, participants in the control group can have their device programmed to deliver appropriate stimulation levels before being reassessed one year later. An improved score would signify an improvement from baseline values whilst"

Answered by AI

Is there an age restriction for participants in this investigation?

"This research is only open to individuals between the ages of 22 and 75."

Answered by AI

Are there any recruitment opportunities for patient participation in this experiment?

"According to clinicaltrials.gov, this research study is not presently enrolling patients, having been first posted on August 1st 2016 and last updated January 4th 2022. Nevertheless, 337 other trials are currently recruiting participants."

Answered by AI

Who else is applying?

What site did they apply to?
The Spine Institute
University of Colorado Hospital
University Hospitals Cleveland Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

I’m sick of being in pain.
PatientReceived no prior treatments
~24 spots leftby Apr 2025